Product
Antipyretic
3 clinical trials
4 indications
Indication
Mucopolysaccharidosis Type 1Indication
Glycogen Storage Disease Type IIIIndication
MedulloblastomaIndication
EpendymomaClinical trial
A Phase III, Single Arm, Cross-over, Multicenter Clinical Trial to Compare Efficacy and Safety of P046 (Laronidase; CinnaGen) Versus Laronidase (Aldurazyme®; Genzyme, BioMarin) in Patients With Mucopolysaccharidosis Type I (MPS I)"Status: Completed, Estimated PCD: 2023-08-12
Clinical trial
A Phase 1/2 First-in-human, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Repeat Doses of UX053 in Patients With GSD IIIStatus: Terminated, Estimated PCD: 2023-03-20
Clinical trial
Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and EpendymomaStatus: Active (not recruiting), Estimated PCD: 2029-10-30